DR. JEFFREY N. MYERS, M.D., PHD, FACS
Medical Practice at Holcombe Blvd, Houston, TX

License number

Texas K4966

Personal information

See more information about JEFFREY N. MYERS at radaris.com

Name

Address

Phone

Jeffrey Myers, age 71

4407 Longacres Ct, Arlington, TX 76016

(817) 457-0492

Jeffrey Myers, age 68

4227 King Cotton Ln, Missouri City, TX 77459

(915) 203-8635

Jeffrey Myers, age 52

5821 County Road 594, Brownwood, TX 76801

Jeffrey Myers, age 50

5307 Cunningham Dr, Pearland, TX 77581

Jeffrey Myers, age 56

5008 Drake Dr, College Station, TX 77845

Organization information

See more information about JEFFREY N. MYERS at bizstanding.com

Jeffrey N Myers MD

1515 Holcombe Blvd #1445, Houston, TX 77030

Categories:

Physicians & Surgeons

Phone:

(713) 792-2121 (Phone)

Professional information

See more information about JEFFREY N. MYERS at trustoria.com

Dr. Jeffrey N Myers, Houston TX - MD (Doctor of Medicine)

Address:

1515 Holcombe Blvd, Houston 77030
MD Anderson Cncr Ctr Hd Nck Sgy
1515 Holcombe Blvd SUITE 1445, Houston 77030
(713) 792-6920 (Phone)

Hospitals:

1515 Holcombe Blvd, Houston 77030
MD Anderson Cncr Ctr Hd Nck Sgy
1515 Holcombe Blvd SUITE 1445, Houston 77030

Education:

Medical Schools
Univ Of Pa Sch Of Med
Graduated: 1991

Imaging Agents And Methods

US Patent:

2010029, Nov 18, 2010

Filed:

May 11, 2007

Appl. No.:

12/227185

Inventors:

Chun Li - Missouri City TX, US
Wei Wang - Sugar Land TX, US
Marites P. Melancon - Houston TX, US
Juri G. Gelovani - Houston TX, US
Jeffrey Myers - Houston TX, US

International Classification:

A61K 49/06, C07D 403/10, C12Q 1/02, A61K 49/00

US Classification:

424 93, 548455, 435 29, 424 91

Abstract:

The disclosure includes a composition including a poly(L-glutamic acid) and a NIRF dye. It also includes a method including providing to a plurality of cells an imaging agent including poly(L-glutamic acid), a NIRF dye and then imaging the cells to detect the imaging agent. It further includes a dual functional contrast agent including an MRI agent conjugated with an optical imaging agent. A method of detecting cancer is provided including injecting a dual functional contrast agent into a patient and performing both an MRI and an optical scan. The presence of the agent may indicate cancer. A method of detecting cancer by injecting PG-DTPA-Gd-NIR813 into a patient, then detecting the presence or absence of Gd in a cell or tissue of the patient and detecting the presence or absence of NIR813 in a cell or tissue of the patient is provided. The presence of Gd and NIR813 may indicate cancer.